Suvajit Koley

Suvajit Koley

Auto-generated profile, based on publicly available information

Suvajit Koley

Department of Chemistry, Saint Louis University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
SKSuvajit Koley
Suvajit Koley
KCKaylee T. Cayton
Kaylee T. Cayton
GGGisela A. González-Montiel
Gisela A. González-Montiel
MYM. Ramu Yadav
M. Ramu Yadav
DODouglas L. Orsi
Douglas L. Orsi
RARyan Altman
Ryan Altman


6 January 2025 in Chemical Communications
Verified
Journal Article
Open access
PDF file
PBPankaj Bhattarai
Pankaj Bhattarai
SKSuvajit Koley
Suvajit Koley
KGKrttika Goel
Krttika Goel
RARyan Altman
Ryan Altman
Fluoroalkyl arenes (Ar–RF) are valuable substructures present in several FDA-approved drugs, patents, agrochemicals, and materials, and complementary strategies that enable access to a broad spectrum of Ar–RF compounds benefit these applied fields. Herein, we report a deoxyfluoroalkylation-aromatization strategy to convert cyclohexanones into a broad-spectrum Ar–RF containing compounds. Generally, the fluoroalkyl sources were activated to participate in a 1,2-addition reaction followed by aromatization in a sequence that contrasts more common preparations of these Ar–RF compounds, such as i) transition-metal catalyzed cross-coupling reactions of aryl electrophiles and nucleophiles, and ii) radical fluoroalkylation reactions of C–H bonds of arenes. Considering the range of cyclohexanone-derived substrates that could be prepared and used, this strategy can be creatively employed to deliver a broad spectrum of highly substituted fluoroalkyl arenes.

1 April 2019 in Journal of Photochemistry and Photobiology A: Chemistry
Verified
Journal Article
Open access
SKSumit Kumar
Sumit Kumar
SKSuvajit Koley
Suvajit Koley
HBHaddad Boumediene
Haddad Boumediene

22 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
GSGabriela P. dos Santos
Gabriela P. dos Santos
IDIngrid de O. Dias
Ingrid de O. Dias
SKSuvajit Koley
Suvajit Koley
MMMarvin J. Meyers
Marvin J. Meyers
Juliana ReimãoJuliana Reimão
Juliana Reimão
Toxoplasmosis, caused by the protozoan Toxoplasma gondii , affects nearly one-third of the global population and may result in severe congenital, ocular, and neurological manifestations. Current therapies are limited by toxicity, poor efficacy against chronic infection, and lack of activity against tissue cysts, highlighting the need for new therapeutic strategies. Aspartic proteases represent promising but underexplored drug targets in T. gondii . In this study, we evaluated the anti- T . gondii potential of a panel of aspartic protease inhibitors initially developed for inhibition of Plasmodium . Eleven compounds were screened in vitro against intracellular tachyzoites (RH strain) in human foreskin fibroblasts (HFF), and their cytotoxicity was assessed to determine EC 50 , CC 50 , and selectivity indices. Most compounds displayed micromolar activity (EC 50 range: 1.06–75.86 µM), with CWHM-032 (=TCMDC-134675), CWHM-033 (=TCMDC-136879), and CWHM-117 emerging as the most potent inhibitors. Based on its in vitro selective activity, predicted pharmacokinetic and safety profile, and previously reported efficacy against experimental malaria, CWHM-117 was selected for in vivo evaluation. In an acute murine model of toxoplasmosis, treatment with CWHM-117 delayed mortality compared to the vehicle-treated group. In a chronic infection model, CWHM-117 significantly reduced cerebral cyst burden ( P < 0.05), demonstrating activity against the bradyzoite stage, which remains a major therapeutic challenge. Overall, these findings indicate that aspartic protease inhibitors, particularly CWHM-117, represent promising lead compounds for the treatment of toxoplasmosis. This study supports T. gondii aspartic proteases as druggable targets and encourages further optimization and mechanistic studies to advance this class of compounds toward preclinical development.

1 October 2025 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PBPankaj Bhattarai
Pankaj Bhattarai
MEMohammed K Abd El-Gaber
Mohammed K Abd El-Gaber
SKSuvajit Koley
Suvajit Koley
RARyan Altman
Ryan Altman